Name | Number of supported studies | Average coverage | |
---|---|---|---|
mast cell | 16 studies | 29% ± 7% | |
natural killer cell | 16 studies | 22% ± 5% | |
CD16-positive, CD56-dim natural killer cell, human | 9 studies | 23% ± 6% | |
type I pneumocyte | 8 studies | 32% ± 15% | |
mature NK T cell | 8 studies | 20% ± 5% | |
mucosal invariant T cell | 7 studies | 22% ± 4% | |
basal cell | 6 studies | 24% ± 5% | |
endothelial cell | 4 studies | 19% ± 4% | |
CD8-positive, alpha-beta T cell | 4 studies | 18% ± 2% | |
microglial cell | 4 studies | 19% ± 2% | |
gamma-delta T cell | 4 studies | 21% ± 1% | |
CD16-negative, CD56-bright natural killer cell, human | 3 studies | 24% ± 6% | |
keratinocyte | 3 studies | 29% ± 6% |
Insufficient scRNA-seq data for expression of ADRB2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 89% | 575.34 | 217 / 245 | 100% | 53.67 | 502 / 502 |
lung | 100% | 1567.11 | 576 / 578 | 69% | 7.80 | 793 / 1155 |
liver | 86% | 571.01 | 195 / 226 | 69% | 8.49 | 281 / 406 |
esophagus | 94% | 654.39 | 1358 / 1445 | 61% | 10.98 | 111 / 183 |
breast | 100% | 3107.24 | 459 / 459 | 53% | 4.14 | 596 / 1118 |
uterus | 63% | 280.08 | 107 / 170 | 66% | 17.40 | 303 / 459 |
skin | 77% | 2281.04 | 1384 / 1809 | 42% | 3.35 | 198 / 472 |
bladder | 67% | 323.29 | 14 / 21 | 46% | 5.44 | 231 / 504 |
spleen | 100% | 789.16 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 6.08 | 1 / 1 |
adipose | 100% | 2468.70 | 1202 / 1204 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 98% | 43.16 | 44 / 45 |
brain | 12% | 36.92 | 314 / 2642 | 82% | 7.34 | 576 / 705 |
muscle | 91% | 466.09 | 730 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 90% | 12.05 | 72 / 80 |
heart | 84% | 390.20 | 724 / 861 | 0% | 0 | 0 / 0 |
stomach | 64% | 254.57 | 230 / 359 | 18% | 1.19 | 52 / 286 |
kidney | 15% | 47.38 | 13 / 89 | 65% | 6.13 | 582 / 901 |
intestine | 58% | 249.08 | 563 / 966 | 14% | 0.92 | 75 / 527 |
lymph node | 0% | 0 | 0 / 0 | 72% | 7.00 | 21 / 29 |
thymus | 34% | 117.67 | 225 / 653 | 35% | 2.45 | 212 / 605 |
peripheral blood | 65% | 395.02 | 601 / 929 | 0% | 0 | 0 / 0 |
pancreas | 0% | 0 | 0 / 328 | 46% | 3.30 | 82 / 178 |
blood vessel | 45% | 186.57 | 602 / 1335 | 0% | 0 | 0 / 0 |
adrenal gland | 2% | 5.89 | 5 / 258 | 22% | 1.58 | 51 / 230 |
ovary | 4% | 20.34 | 8 / 180 | 8% | 0.37 | 35 / 430 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006939 | Biological process | smooth muscle contraction |
GO_0006366 | Biological process | transcription by RNA polymerase II |
GO_0050873 | Biological process | brown fat cell differentiation |
GO_0045986 | Biological process | negative regulation of smooth muscle contraction |
GO_0007188 | Biological process | adenylate cyclase-modulating G protein-coupled receptor signaling pathway |
GO_0071880 | Biological process | adenylate cyclase-activating adrenergic receptor signaling pathway |
GO_0002028 | Biological process | regulation of sodium ion transport |
GO_0007171 | Biological process | activation of transmembrane receptor protein tyrosine kinase activity |
GO_0006898 | Biological process | receptor-mediated endocytosis |
GO_0002024 | Biological process | diet induced thermogenesis |
GO_1990911 | Biological process | response to psychosocial stress |
GO_2000969 | Biological process | positive regulation of AMPA receptor activity |
GO_1904504 | Biological process | positive regulation of lipophagy |
GO_0043410 | Biological process | positive regulation of MAPK cascade |
GO_0040015 | Biological process | negative regulation of multicellular organism growth |
GO_0002025 | Biological process | norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure |
GO_0045744 | Biological process | negative regulation of G protein-coupled receptor signaling pathway |
GO_0061885 | Biological process | positive regulation of mini excitatory postsynaptic potential |
GO_0010739 | Biological process | positive regulation of protein kinase A signaling |
GO_0008333 | Biological process | endosome to lysosome transport |
GO_0009409 | Biological process | response to cold |
GO_0031649 | Biological process | heat generation |
GO_0045453 | Biological process | bone resorption |
GO_0120162 | Biological process | positive regulation of cold-induced thermogenesis |
GO_2000481 | Biological process | positive regulation of cAMP-dependent protein kinase activity |
GO_1901098 | Biological process | positive regulation of autophagosome maturation |
GO_0071875 | Biological process | adrenergic receptor signaling pathway |
GO_0030501 | Biological process | positive regulation of bone mineralization |
GO_0071902 | Biological process | positive regulation of protein serine/threonine kinase activity |
GO_1904646 | Biological process | cellular response to amyloid-beta |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0007166 | Biological process | cell surface receptor signaling pathway |
GO_0016324 | Cellular component | apical plasma membrane |
GO_0098992 | Cellular component | neuronal dense core vesicle |
GO_0043235 | Cellular component | receptor complex |
GO_0005886 | Cellular component | plasma membrane |
GO_0016020 | Cellular component | membrane |
GO_0005769 | Cellular component | early endosome |
GO_0005764 | Cellular component | lysosome |
GO_0030669 | Cellular component | clathrin-coated endocytic vesicle membrane |
GO_0005794 | Cellular component | Golgi apparatus |
GO_0010008 | Cellular component | endosome membrane |
GO_0005768 | Cellular component | endosome |
GO_0005634 | Cellular component | nucleus |
GO_0042803 | Molecular function | protein homodimerization activity |
GO_0044877 | Molecular function | protein-containing complex binding |
GO_0001540 | Molecular function | amyloid-beta binding |
GO_0042802 | Molecular function | identical protein binding |
GO_0051380 | Molecular function | norepinephrine binding |
GO_0015459 | Molecular function | potassium channel regulator activity |
GO_0008179 | Molecular function | adenylate cyclase binding |
GO_0005515 | Molecular function | protein binding |
GO_0004941 | Molecular function | beta2-adrenergic receptor activity |
Gene name | ADRB2 |
Protein name | Beta-2 adrenergic receptor (Beta-2 adrenoceptor) (Beta-2 adrenoreceptor) Beta-2 adrenergic receptor (Beta-2 adrenoreceptor) (Beta-2 adrenoceptor) ADRB2 protein |
Synonyms | B2AR ADRB2R |
Description | FUNCTION: Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine. . FUNCTION: Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine. . FUNCTION: Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine. . |
Accessions | A2N4T7 Q9BYZ0 X5DQM5 P07550 ENST00000305988.6 |